e-Drug3D

1451

DEGARELIX

INN
DEGARELIX

cas 214766-78-6

CLASS

ANTINEOPLASTIC
PROSTATE CANCER
GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONIST
IT BINDS REVERSIBLY TO THE PITUITARY GNRH RECEPTORS THEREBY REDUCING THE RELEASE OF GONADOTROPINS AND CONSEQUENTLY TESTOSTERONE

ROUTE (list)

SUBCUTANEOUS INJECTION

ATC code

L02BX02

PK parameters

VD 1000 LITER
Cl 9 LITER / HOUR
PPB 90 PERCENT
t1/2 1272 HOUR

Target

TARGET GONADOTROPIN-RELEASING HORMONE

DrugCentral

Gonadotropin-releasing hormone receptor UNIPROT P30968 GNRHR

Download SDF file

D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- (9CI)

Formula:
C82H103ClN18O16

Calculated chemical properties:

MW 1632.27
NB_atoms 117
XLogP 1.51
PSA 471.034
NB_HD 19
NB_HA 34
fsp3 0.41
Lipinski(0=no;1=yes) 0

FDA
NDA 022201 (label) INN (DEGARELIX ACETATE) FIRMAGON (FERRING) APPROVAL= AP YEAR= 2008
NDA 215791 (pdf not found) INN (DEGARELIX ACETATE) DEGARELIX ACETATE (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.) APPROVAL= TA YEAR= 2025